

Lee's Pharm (Zhaoke) Sparkled on The 92nd PharmChina (Shanghai)

On May 13, 2026, The 92nd PharmChina was kicked off at the National Exhibition and Convention Center in Shanghai. As a leading professional trade and exchange exhibition platform for the pharmaceutical and healthcare industry, more than thousands of pharmaceutical companies and 100,000 professionals were gathered at this fair. Lee's Pharmaceutical Holdings Ltd. (Lee's Pharm or Lee's Group, Stock Code: 00950.HK) showcased with a diverse portfolio of innovative and flagship products, exhibiting and highlighting for maximizing success at this three-day trade. The exhibition was bustling with visitors and lively atmosphere.



During the exhibition, Lee's Pharm marked the first time conducting live streaming with a dual-platform of WeChat Channels and Xiaohongshu. The livestreams delivering at different time slots had guided with a "Virtual Tour" of walking on-site around the exhibition, showcased the company's booths and brought live features for online audiences. The interactions with likes and comments generated from audiences were very enthusiastic, while further promoting the brands across new media channels.



Lee's Pharm exhibited at the fair with a wide range of products covering various therapeutic areas including rare diseases, dermatology, women's health and pediatrics. The newly introduced prasterone vaginal pessary (Intrarosa[®]) and iron proteinsuccinylate oral solution (Ferplex[®]) of which has entered the OTC channel as well, had attracted considerable attention among visitors. Meanwhile, the flagship products likely the human interferon alfa-2b gel (Yallaferon[®]), Adapalene and Clindamycin hydrochloride gel (馥霖安[®]), and Epinastine hydrochloride tablets (悅忒紓[®]) are continued a stirring of interest in consumers, reflecting the Group's solid R&D capabilities and the vitality of its product portfolio.

Throughout the exhibition, the Group's sales & marketing team presented themselves with professional expertise for constructive and productive discussions among representatives of distributors, chain pharmacies and medical entities from all over the country, laying a solid foundation for future collaboration.



Looking ahead, Lee's Pharm will continue to endeavor on its enterprise mission as dedicating to develop innovative drugs, contributing to unmet medical needs, improving patients' quality of life and delivering better care for patients. The Group will continue to work closely with partners to tackle barriers for achieving sustainable development in the pharmaceutical and healthcare industry.

About Lee's Pharm

Lee's Pharm is a research-driven and market-oriented biopharmaceutical company with 30 years of operation in the pharmaceutical industry in China. The Group is fully integrated with solid infrastructures in drug development, clinical development, regulatory affairs, manufacturing, sales and marketing based in Mainland China. The Company has established extensive partnerships with around 30 international companies and currently markets over 25 proprietary, generic and in-licensed pharmaceutical products in Mainland China, Hong Kong, Macau and Taiwan. Lee's Pharm focuses on several key disease areas such as cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology and obstetrics, and has more than 40 products at different stages of development stemming from internal research and development, as well as the licensing of development, commercialization, and manufacturing rights from various United States, European and Japanese companies. For more information, please visit www.leespharm.com.

Contact person:

Vivian Fung

Tel: +852 2314 1282 | Email: info@leespharm.com